Available Forms
Combining CJC-1295 no DAC and Ipamorelin is a standard approach in secretagogue research. It maximizes GH output while avoiding the receptor desensitization and side effects associated with exogenous GH.
Supply duration: 8 to 12 weeks continuous administration
CJC-1295 binds GHRH receptors while Ipamorelin activates GHS-R1a ghrelin receptors on pituitary somatotrophs. This dual signaling amplifies growth hormone release beyond what either peptide achieves individually, maintaining natural pulsatile rhythms without elevating stress hormones.
PURITY CHECK
HPLC Chromatogram provided with every shipment.
ZERO FILLERS
Free of residual solvents, heavy metals, or unlisted buffers.
SECURE DELIVERY
Discreet, protective thermal packaging.
It targets two separate pituitary receptor pathways (GHRH and GHS-R1a) simultaneously, increasing total GH release.
You can feel it in your focus, your recovery, and your daily rhythm.
Three simple steps for a desired outcome
Proper storage and handling of laboratory reagents in vial format is crucial for ensuring their effectiveness and reliability. To maintain their integrity, it's important to follow specific guidelines for temperature control, light exposure, and contamination prevention.
